- No active or chronic hepatitis infection. HCV antibody (for Hepatitis C) and Hepatitis B Surface antigen must be negative. This has been routinely incorporated into immunotherapy trials with checkpoint inhibitors because of concerns that the risk of treatment-induced hepatic injury is increased in the setting of active viral hepatitis.